Mucinous ovarian carcinoma: Slippery business

Cancer

Volumn 117, Issue 3, 2011, Pages 451-453

  Soslow, Robert A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYTOKERATIN 20; CYTOKERATIN 7; PROTEIN P16; SMAD4 PROTEIN;

CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; EDITORIAL; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR GENETICS; MUCINOUS CARCINOMA; OVARY CARCINOMA; OVARY METASTASIS; PERITONEUM PSEUDOMYXOMA; PRIORITY JOURNAL; SURVIVAL RATE; TERATOMA;

ADENOCARCINOMA, MUCINOUS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; FEMALE; HUMANS; INTESTINAL NEOPLASMS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 79251491360     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25453     Document Type: Editorial

References (20)

1. Zaino RJ, Brady MF, Lele SM, et al. Advanced Stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer. 2011; 117: 554-662.
2. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM., The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004; 23: 41-44.
3. Seidman JD, Kurman RJ, Ronnett BM., Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003; 27: 985-993.
4. Riopel MA, Ronnett BM, Kurman RJ., Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol. 1999; 23: 617-635.
5. Ronnett BM, Kurman RJ, Shmookler BM, Sugarbaker PH, Young RH., The morphologic spectrum of ovarian metastases of appendiceal adenocarcinomasâ a clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors or metastatic tumors from other gastrointestinal sites. Am J Surg Pathol. 1997; 21: 1144-1155.
6. Ronnett BM, Shmookler BM, Diener-West M, Sugarbaker PH, Kurman RJ., Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int J Gynecol Pathol. 1997; 16: 1-9.
7. Vang R, Gown AM, Zhao C, et al. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. Am J Surg Pathol. 2007; 31: 854-869.
8. McKenney JK, Soslow RA, Longacre TA., Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol. 2008; 32: 645-655.
9. Yemelyanova AV, Vang R, Judson K, Wu LS, Ronnett BM., Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol. 2008; 32: 128-138.
10. Lee KR, Young RH., The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol. 2003; 27: 281-292.
11. Vang R, Gown AM, Barry TS, et al. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol. 2006; 30: 1130-1139.
12. Logani S, Oliva E, Arnell PM, Amin MB, Young RH., Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol. 2005; 18: 19-25.
13. Vang R, Gown AM, Farinola M, et al. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol. 2007; 31: 653-663.
14. Ji H, Isacson C, Seidman JD, Kurman RJ, Ronnett BM., Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol. 2002; 21: 391-400.
15. Gemignani ML, Schlaerth AC, Bogomolniy F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol. 2003; 90: 378-381.
16. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR., Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009; 76: 1-18.
17. Köbel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD., Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol. 2010; 116: 50-56.
18. Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP., In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol. 2004; 92: 160-166.
19. McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Köbel M, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 2009; 9: 433.
20. Soslow RA., Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol. 2008; 27: 161-174.